Healthcare [ 10/13 ] | Drug Manufacturers - Specialty & Generic [ 58/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | -7.16 Decreased by -1.16 K% | - |
| Aug 8, 23 | -7.55 Decreased by -171.69% | - |
| May 11, 23 | -28.6 Decreased by -1.38 K% | -31.2 Increased by +8.33% |
| Mar 9, 23 | 0.44 Increased by +125.31% | -0.15 Increased by +391.93% |
| Nov 1, 22 | -0.57 Increased by +60.14% | -0.1 Decreased by -470% |
| Aug 4, 22 | -2.78 Decreased by -48.66% | -0.36 Decreased by -672.22% |
| May 11, 22 | -1.93 Increased by +21.54% | -0.39 Decreased by -394.87% |
| Mar 9, 22 | -1.73 Increased by +30.8% | -1.11 Decreased by -55.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 27.71 M Decreased by -17.3% | -8.89 M Increased by +35.85% | Decreased by -32.07% Increased by +22.43% |
| Jun 30, 23 | 29.68 M Decreased by -4.43% | -9.38 M Increased by +79.9% | Decreased by -31.61% Increased by +78.97% |
| Mar 31, 23 | 22.26 M Decreased by -1.22% | -16.82 M Increased by +31.39% | Decreased by -75.59% Increased by +30.54% |
| Dec 31, 22 | 31.47 M Decreased by -14.86% | 19.14 M Increased by +193.07% | Increased by +60.82% Increased by +209.32% |
| Sep 30, 22 | 33.51 M Increased by +6.53% | -13.85 M Increased by +48.82% | Decreased by -41.34% Increased by +51.96% |
| Jun 30, 22 | 31.05 M Decreased by -2.31% | -46.68 M Decreased by -104.17% | Decreased by -150.34% Decreased by -109% |
| Mar 31, 22 | 22.53 M Decreased by -21.93% | -24.52 M Increased by +26.69% | Decreased by -108.82% Increased by +6.11% |
| Dec 31, 21 | 36.97 M Decreased by -3.13% | -20.57 M Increased by +75.23% | Decreased by -55.64% Increased by +74.44% |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.